PTGS2 and breast cancer: Among breast cancer patients who received chemotherapy, none of eight patients with increased Yap1-Cox2 signature scores had a pathological complete response (pCR), while five of seven patients with lower Yap1-Cox2 signature scores had pCR (Fig. 8f), suggesting that increased Yap1-Cox2 signaling is also associated with adaptive resistance to chemotherapies in these patients.